Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 May;47(5):538-548.
doi: 10.1007/s00134-021-06388-0. Epub 2021 Apr 14.

Evolving changes in mortality of 13,301 critically ill adult patients with COVID-19 over 8 months

Affiliations
Multicenter Study

Evolving changes in mortality of 13,301 critically ill adult patients with COVID-19 over 8 months

Pedro Kurtz et al. Intensive Care Med. 2021 May.

Abstract

Purpose: Clinical characteristics and management of COVID-19 patients have evolved during the pandemic, potentially changing their outcomes. We analyzed the associations of changes in mortality rates with clinical profiles and respiratory support strategies in COVID-19 critically ill patients.

Methods: A multicenter cohort of RT-PCR-confirmed COVID-19 patients admitted at 126 Brazilian intensive care units between February 27th and October 28th, 2020. Assessing temporal changes in deaths, we identified distinct time periods. We evaluated the association of characteristics and respiratory support strategies with 60-day in-hospital mortality using random-effects multivariable Cox regression with inverse probability weighting.

Results: Among the 13,301 confirmed-COVID-19 patients, 60-day in-hospital mortality was 13%. Across four time periods identified, younger patients were progressively more common, non-invasive respiratory support was increasingly used, and the 60-day in-hospital mortality decreased in the last two periods. 4188 patients received advanced respiratory support (non-invasive or invasive), from which 42% underwent only invasive mechanical ventilation, 37% only non-invasive respiratory support and 21% failed non-invasive support and were intubated. After adjusting for organ dysfunction scores and premorbid conditions, we found that younger age, absence of frailty and the use of non-invasive respiratory support (NIRS) as first support strategy were independently associated with improved survival (hazard ratio for NIRS first [95% confidence interval], 0.59 [0.54-0.65], p < 0.001).

Conclusion: Age and mortality rates have declined over the first 8 months of the pandemic. The use of NIRS as the first respiratory support measure was associated with survival, but causal inference is limited by the observational nature of our data.

Keywords: Coronavirus; In-hospital mortality; Non-invasive ventilation; Respiratory support.

PubMed Disclaimer

Conflict of interest statement

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. MS and JIFS are founders and equity shareholders of Epimed Solutions®, which commercializes the Epimed Monitor System®, a cloud-based software for ICU management and benchmarking. The other authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Progression of adult ICU admissions with COVID-19 from February 27th, 2020 to October 28th, 2020. a Total patients in the ICU per day; b the number of new ICU admissions per day; c the number of deaths in the ICU per day; and d the daily mortality rate in the ICU (using the admission date as the reference). The black line represents daily absolute numbers, and the blue line is the smoothed curve. The three dashed lines correspond to the estimated breakpoints of structure change in the time series of ICU deaths rate panel (c): April 25th, June 06th, and August 10th, respectively.
Fig. 2
Fig. 2
Univariable survival curves (Kaplan–Meier) of factors related to the 60-day outcome in critically ill patients who underwent advanced respiratory support. a Time periods estimated with the breakpoints of structure change (Period 1: February 27th to April 25th; Period 2: April 26th to June 6th; Period 3: June 7th to August 10th; Period 4: August 11th to October 28th); b age (< 40, 40–49, 50–59, 60–69, 70–79, and ≥ 80; c Modified Frailty Index (MFI) at the admission, with groups non-frail (MFI = 0), pre-frail (MFI = 1–2) and frail (MFI ≥ 3); and d initial respiratory support considering non-invasive (NIRS first) invasive (IMV first). Differences among curves were assessed using the log-rank test with a confidence level of 0.05.
Fig. 3
Fig. 3
Random-effects multivariable cox proportional hazards model to assess the association of clinical characteristics and initial respiratory support with 60-day mortality in patients who underwent advanced ventilatory support (NIRS and/or IMV), adjusted by the time-period of admission. The hospital was considered as the random intercept (standard deviation = 0.50). To account for the non randomization, we used inverse-probability treatment weighting (IPTW) of propensity scores regarding the initial use of NIRS. We provide the hazard ratio (HR) for 60-day in-hospital mortality and its respective 95% confidence intervals for each variable

Comment in

Similar articles

Cited by

References

    1. Van Damme W, Dahake R, Delamou A, et al. The COVID-19 pandemic: diverse contexts; different epidemics—how and why? BMJ Glob Health. 2020;5:e003098. doi: 10.1136/bmjgh-2020-003098. - DOI - PMC - PubMed
    1. Taylor L. How Latin America is fighting covid-19, for better and worse. BMJ. 2020 doi: 10.1136/bmj.m3319. - DOI - PubMed
    1. Boehmer TK, DeVies J, Caruso E, et al. Changing Age Distribution of the COVID-19 Pandemic—United States, May–August 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1404–1409. doi: 10.1585/mmwr.mm6939e1. - DOI - PMC - PubMed
    1. Committee TW, for the REMAP-CAP Investigators, Angus DC, Derde L,, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 doi: 10.1001/jama.2020.17022. - DOI - PMC - PubMed
    1. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020 doi: 10.1001/jama.2020.17021. - DOI - PMC - PubMed

Publication types

LinkOut - more resources